CA2702635A1 - A new biomarker for monitoring development of diseases and assessing the efficacy of therapies - Google Patents

A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Download PDF

Info

Publication number
CA2702635A1
CA2702635A1 CA2702635A CA2702635A CA2702635A1 CA 2702635 A1 CA2702635 A1 CA 2702635A1 CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A1 CA2702635 A1 CA 2702635A1
Authority
CA
Canada
Prior art keywords
disease
sample
protein
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2702635A
Other languages
English (en)
French (fr)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2702635A1 publication Critical patent/CA2702635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CA2702635A 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Abandoned CA2702635A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
CA2702635A1 true CA2702635A1 (en) 2009-04-30

Family

ID=38656804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702635A Abandoned CA2702635A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2389751T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2503338E (https=)
SI (2) SI2503338T1 (https=)
WO (1) WO2009053523A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
EP0862652A1 (en) 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
PT2503338E (pt) 2015-03-05
WO2009053523A1 (en) 2009-04-30
ES2532361T3 (es) 2015-03-26
EP2201376B1 (en) 2012-08-08
EP2503338B1 (en) 2014-12-24
JP5619810B2 (ja) 2014-11-05
PL2201376T3 (pl) 2013-01-31
SI2503338T1 (sl) 2015-06-30
US20100209942A1 (en) 2010-08-19
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
JP2012159514A (ja) 2012-08-23
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP4982610B2 (ja) 2012-07-25
ES2389751T3 (es) 2012-10-31
CY1116089T1 (el) 2017-02-08
PL2503338T3 (pl) 2015-06-30
EP2503338A2 (en) 2012-09-26
JP2011501176A (ja) 2011-01-06
CY1113403T1 (el) 2016-06-22
KR20160029869A (ko) 2016-03-15
SI2201376T1 (sl) 2012-09-28
KR20100059902A (ko) 2010-06-04
DK2503338T3 (en) 2015-03-09
HRP20150181T1 (hr) 2015-06-19
EP2503338A3 (en) 2013-03-13
PT2201376E (pt) 2012-08-20

Similar Documents

Publication Publication Date Title
EP2201376B1 (en) A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
Diamant et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper
Romagnani et al. CXCL10: a candidate biomarker in transplantation
US8975081B2 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
Chaiworapongsa et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award
CA2744434C (en) Methods, devices and kits for detecting or monitoring acute kidney injury
Alturaiki et al. Assessment of IL‐1β, IL‐6, TNF‐α, IL‐8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis
JP2025019061A (ja) 術後有害事象の診断または予後
JP2010519898A (ja) ライノウイルス感染を制御するための化合物の同定方法及び標的
US20090011444A1 (en) Detection and diagnosis of inflammatory disorders
Obiefuna et al. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2, 6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma
Tian et al. Serum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit
KR20190039089A (ko) 결장직장암에 대한 복합 테스트
Engebretsen et al. Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats
Gatselis et al. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
Rumora et al. Assessment of NLRP3 inflammasome activation in patients with chronic obstructive pulmonary disease before and after lung transplantation
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
US20110033876A1 (en) Method for diagnosing pulmonary artery hypertension
CN116801788A (zh) 用于评估肝脏疾病的试剂盒、试剂和方法
CN111094981B (zh) Pct和pro-adm作为监测抗生素治疗的标记物
WO2011125858A1 (ja) バイオマーカー
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
Sumi et al. Regional variations in allergen-induced airway inflammation corresponds to changes in soluble guanylyl cyclase heme and expression of heme-oxygenase-1
Dutta et al. Diagnosis of infected pancreatic necrosis: A review of the role of blood biomarkers
Sandström et al. Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130827

FZDE Discontinued

Effective date: 20201005